ZA200803659B - Use of complement pathway inhibitors to treat ocular disease - Google Patents

Use of complement pathway inhibitors to treat ocular disease

Info

Publication number
ZA200803659B
ZA200803659B ZA200803659A ZA200803659A ZA200803659B ZA 200803659 B ZA200803659 B ZA 200803659B ZA 200803659 A ZA200803659 A ZA 200803659A ZA 200803659 A ZA200803659 A ZA 200803659A ZA 200803659 B ZA200803659 B ZA 200803659B
Authority
ZA
South Africa
Prior art keywords
complement pathway
ocular disease
pathway inhibitors
treat ocular
treat
Prior art date
Application number
ZA200803659A
Other languages
English (en)
Inventor
Fung Sek Chung
Yao Zhengbin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38023865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200803659(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA200803659B publication Critical patent/ZA200803659B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
ZA200803659A 2005-11-04 2006-11-04 Use of complement pathway inhibitors to treat ocular disease ZA200803659B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73376305P 2005-11-04 2005-11-04

Publications (1)

Publication Number Publication Date
ZA200803659B true ZA200803659B (en) 2009-07-29

Family

ID=38023865

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200803659A ZA200803659B (en) 2005-11-04 2006-11-04 Use of complement pathway inhibitors to treat ocular disease
ZA2013/00649A ZA201300649B (en) 2005-11-04 2013-01-24 Use of complement pathway inhibitors to treat ocular diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2013/00649A ZA201300649B (en) 2005-11-04 2013-01-24 Use of complement pathway inhibitors to treat ocular diseases

Country Status (29)

Country Link
US (3) US8753625B2 (de)
EP (4) EP2998318A1 (de)
JP (7) JP2009514888A (de)
KR (6) KR101511787B1 (de)
CN (2) CN101355956A (de)
AU (1) AU2006311803C1 (de)
BR (1) BRPI0619657A2 (de)
CA (2) CA2624393C (de)
CR (1) CR10041A (de)
DK (1) DK2500030T4 (de)
EC (1) ECSP088500A (de)
ES (1) ES2551202T5 (de)
HK (2) HK1175718A1 (de)
HU (1) HUE026423T2 (de)
IL (3) IL190547A (de)
MA (1) MA29976B1 (de)
MX (3) MX360959B (de)
MY (1) MY151064A (de)
NO (1) NO20082483L (de)
NZ (2) NZ567483A (de)
PH (1) PH12013501270A1 (de)
PL (1) PL2500030T5 (de)
PT (1) PT2500030E (de)
RU (2) RU2417099C2 (de)
SG (1) SG10201804008UA (de)
SI (1) SI2500030T2 (de)
UA (1) UA99591C2 (de)
WO (1) WO2007056227A2 (de)
ZA (2) ZA200803659B (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
WO2006096561A2 (en) 2005-03-04 2006-09-14 Duke University Genetic variants increase the risk of age-related macular degeneration
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
CA2656063C (en) 2006-06-21 2016-10-18 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
AU2007307375B2 (en) 2006-10-10 2013-11-28 Regenesance B.V. Complement inhibition for improved nerve regeneration
PL2097455T3 (pl) 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
KR20100015773A (ko) * 2007-03-22 2010-02-12 노파르티스 아게 Ｃ５ 항원 및 그의 용도
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
CN101970002B (zh) * 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
MX2010005115A (es) * 2007-11-08 2010-05-27 Genentech Inc Anticuerpos anti-factor b y sus usos.
US20110182910A1 (en) * 2008-03-06 2011-07-28 Medof M Edward Method of treating t cell mediated disorders
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
AU2013200637B2 (en) * 2008-04-28 2015-07-16 Genentech, Inc. Humanized anti-Factor D antibodies and uses thereof
SI2320925T1 (sl) * 2008-07-10 2016-05-31 Regenesance B.V. Komplement antagonisti in njih uporaba
MX2011001371A (es) 2008-08-05 2011-06-16 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5.
US8092013B2 (en) * 2008-10-28 2012-01-10 Johnson & Johnson Vision Care, Inc. Apparatus and method for activation of components of an energized ophthalmic lens
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2496259B1 (de) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Behandlung von paroxysmaler nächtlicher hämoglobinurie
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
EP2533797A1 (de) 2010-02-12 2012-12-19 CeMM Forschungszentrum für Molekulare Medizin GmbH Komplement-faktor h für krankheitsstadien bei oxidativem stress
WO2011112993A2 (en) 2010-03-11 2011-09-15 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
EA201291328A1 (ru) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
HUE057267T2 (hu) * 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
MX348025B (es) 2010-11-01 2017-05-24 Genentech Inc * Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2012075023A2 (en) * 2010-11-29 2012-06-07 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
SG194780A1 (en) 2011-05-05 2013-12-30 Wellstat Immunotherapeutics Llc Complement factor b analogs and their uses
RU2653439C9 (ru) * 2011-05-11 2018-10-16 Апеллис Фармасьютикалс, Инк. Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
US10588879B2 (en) * 2011-08-01 2020-03-17 Aurin Biotech Inc. Treatment of age-related macular degeneration
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
PT2817329T (pt) * 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polipeptioos que se ligam ao complemento humano c5
WO2013142362A1 (en) * 2012-03-19 2013-09-26 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
JP6244350B2 (ja) 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
EP2855529A4 (de) 2012-05-24 2015-12-09 Alexion Pharma Inc Humanisierte anti-faktor-b-antikörper
EP2864322B1 (de) * 2012-06-20 2016-04-27 Novartis AG Modulatoren des komplementweges und verwendungen davon
KR102073312B1 (ko) 2012-06-27 2020-02-05 엘지전자 주식회사 당뇨망막병증 진단용 마커 및 이의 용도
CN102743371A (zh) * 2012-07-26 2012-10-24 山东省眼科研究所 一种治疗视网膜新生血管性疾病的药物
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013326932B2 (en) 2012-10-04 2019-06-06 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
EP3660033B9 (de) 2012-11-15 2022-06-22 Apellis Pharmaceuticals, Inc. Langwirkende compstatin-analoga sowie verwandte zusammensetzungen und verfahren
BR112015018438A2 (pt) * 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN105229003B (zh) 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EP4302736A3 (de) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Ophthalmisches implantat zur abgabe von therapeutischen substanzen
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
SG11201510315TA (en) 2013-07-12 2016-01-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
KR20180021234A (ko) * 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
AU2014332021B2 (en) * 2013-10-07 2020-05-07 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
CA2934462A1 (en) 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
CA2939586A1 (en) * 2014-02-27 2015-09-03 Allergan, Inc. Complement factor bb antibodies
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
ES2750556T3 (es) 2014-06-12 2020-03-26 Ra Pharmaceuticals Inc Modulación de actividad del complemento
WO2016022750A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
EP3183266B1 (de) * 2014-08-20 2019-05-29 Stichting Sanquin Bloedvoorziening Faktor-h-spezifische antikörper und verwendungen davon
CN107172879B (zh) 2014-11-10 2021-11-05 豪夫迈·罗氏有限公司 抗白细胞介素-33抗体及其用途
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN108291216B (zh) * 2015-09-24 2022-09-16 宾夕法尼亚州大学信托人 用于治疗补体介导的疾病的组合物和方法
EP3359555B1 (de) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosierpläne
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
EP3368682B1 (de) 2015-10-30 2019-12-11 H. Hoffnabb-La Roche Ag Verfahren zur messung der faktor-d-aktivität und potenz von faktor-d-inhibitoren
PT3685847T (pt) 2015-12-16 2023-03-14 Ra Pharmaceuticals Inc Moduladores de atividade de complemento
JP7199966B2 (ja) 2015-12-23 2023-01-06 ソルボンヌ ウニベルシテ ＣＤ１１ｂ／ＣＤ１８に対するＣＦＨの結合を阻害する薬剤、およびその使用
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
IL311675A (en) 2016-04-04 2024-05-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
SI3468990T1 (sl) 2016-06-14 2024-07-31 Regeneron Pharmaceuticals, Inc. Protitelesa proti-C in njihove uporabe
EP3551210A1 (de) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulatoren der komplementaktivität
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
KR20230173731A (ko) 2017-01-30 2023-12-27 알렉시온 파마슈티칼스, 인코포레이티드 1가 항-프로페르딘 항체 및 항체 단편
EP3580241A4 (de) * 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania Antifaktor-d-antikörper und verwendungen davon
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
JP2020532285A (ja) 2017-07-11 2020-11-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
EP3694874A1 (de) * 2017-10-11 2020-08-19 Bioverativ USA Inc. Verfahren zur induktion von komplementaktivität
MX2020005547A (es) 2017-12-04 2020-08-20 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
MX2020010323A (es) 2018-04-03 2021-01-08 Ngm Biopharmaceuticals Inc Agentes de union al componente del complemento c3 (c3) y metodos para su uso.
EP3791180A1 (de) * 2018-05-10 2021-03-17 The University Of Manchester Verfahren zur beurteilung von makuladegeneration
EP3586865A1 (de) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
US20230115176A1 (en) 2019-03-29 2023-04-13 Ra Pharmaceuticals, Inc. Complement Modulators and Related Methods
WO2020219822A1 (en) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
KR20220057530A (ko) 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
KR102428619B1 (ko) 2019-09-25 2022-08-04 대구가톨릭대학교산학협력단 망막병증 치료용 약물 방출 콘택트렌즈 및 이의 제조방법
MX2022011156A (es) 2020-03-13 2022-10-13 Genentech Inc Anticuerpos anti-interleucina-33 y usos de estos.
AU2021261257A1 (en) 2020-04-20 2022-12-22 Genzyme Corporation Humanized anti-complement factor Bb antibodies and uses thereof
CN114686481B (zh) * 2020-12-31 2023-08-15 北京键凯科技股份有限公司 一种抑制cfd表达的干扰rna及其制备方法和应用
TW202415387A (zh) * 2022-06-30 2024-04-16 美商伊維希比奥公司 用於治療眼科疾患之持續釋放二氧化矽水凝膠複合物及其使用方法

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5022A (en) * 1847-03-20 Alfred stillman
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0368684B2 (de) 1988-11-11 2004-09-29 Medical Research Council Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
ES2129029T5 (es) 1990-10-05 2005-10-16 Celldex Therapeutics, Inc. Inmunoestimulacion dirigida con reactivos biespecificos.
EP0557300B1 (de) 1990-10-29 1997-11-19 Chiron Corporation Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
CA2095836C (en) 1990-11-09 1999-04-06 Stephen D. Gillies Cytokine immunoconjugates
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU665758B2 (en) 1991-04-26 1996-01-18 Surface Active Limited Novel antibodies, and methods for their use
ATE199647T1 (de) 1991-05-14 2001-03-15 Univ Connecticut Gerichtete abgabe von genen, die immunogene proteine kodieren
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE195656T1 (de) 1991-06-05 2000-09-15 Univ Connecticut Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69332948T2 (de) 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
HU218069B (hu) 1992-06-09 2000-05-28 Hoppe Ag. Kilincses zárrendszer
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
EP0749475A4 (de) 1992-08-26 1997-05-07 Harvard College Verwendung des cytokins ip-10 als anti-tumor agenz
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE200625T1 (de) 1992-10-09 2001-05-15 Advanced Tissue Sciences Inc Leberreservezellen
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
AU2191795A (en) * 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679564A (en) * 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
EP1709970A1 (de) 1995-04-27 2006-10-11 Abgenix, Inc. Menschliche Antikörper gegen EGFR, von immunisierten transgenen Mäusen produziert
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU715543B2 (en) 1995-09-08 2000-02-03 Genzyme Corporation Improved AAV vectors for gene therapy
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP2000508522A (ja) 1996-03-22 2000-07-11 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド アポトーシス誘導分子ｉｉ
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6410708B1 (en) * 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
ATE335511T1 (de) * 1997-08-26 2006-09-15 Amgen Fremont Inc Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
KR20010031713A (ko) 1997-11-03 2001-04-16 벤슨 로버트 에이치. 맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제
US6595142B2 (en) 1997-11-13 2003-07-22 M.C.M. Holding A/S Floor for a transport means and profiles for the construction thereof as well as a vehicle provided with such a floor
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
ES2488819T3 (es) * 1998-02-20 2014-08-29 Genentech, Inc. Inhibidores de la activación del complemento
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
EP1141285A2 (de) 1998-12-16 2001-10-10 Genentech, Inc. Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäure
JP3993746B2 (ja) 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CZ303128B6 (cs) 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １８個のヒト分泌タンパク質
EP1690872A3 (de) 1999-12-01 2006-08-23 Genentech, Inc. Zusammensetzung und Verfahren zur Diagnose eines Tumors
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
ATE435873T1 (de) 2000-03-23 2009-07-15 Genentech Inc Anti-c2/c2a inhibitoren zur komplement aktivierung
DE60136272D1 (de) * 2000-04-29 2008-12-04 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2113516B1 (de) * 2000-10-10 2014-05-21 Genentech, Inc. C5 Antikörper, die die Typ II Aktivierung von Endothelialzellen inhibieren
WO2002030986A2 (en) 2000-10-13 2002-04-18 Biogen, Inc. HUMANIZED ANTI-LT-β-R ANTIBODIES
US20040077575A1 (en) * 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
EP1425042B2 (de) * 2001-08-17 2016-02-10 Genentech, Inc. KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
WO2005025516A2 (en) * 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
US7816497B2 (en) * 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
RU2232991C1 (ru) 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
ES2375490T3 (es) * 2004-11-18 2012-03-01 Yale University Métodos y composiciones para diagnosticar degeneración macular relacionada con la edad.
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
CN103920142A (zh) * 2005-02-14 2014-07-16 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
PL1951279T3 (pl) * 2005-10-08 2017-12-29 Apellis Pharmaceuticals, Inc. Kompstatyna i jej analogi w zaburzeniach oczu
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
PL2097455T3 (pl) * 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Also Published As

Publication number Publication date
PT2500030E (pt) 2015-09-24
CN101355956A (zh) 2009-01-28
JP2009280626A (ja) 2009-12-03
KR20080065693A (ko) 2008-07-14
WO2007056227A2 (en) 2007-05-18
KR20150055628A (ko) 2015-05-21
IL190547A0 (en) 2008-11-03
KR20170002684A (ko) 2017-01-06
PL2500030T3 (pl) 2015-12-31
RU2417099C2 (ru) 2011-04-27
WO2007056227A3 (en) 2007-10-11
IL190547A (en) 2017-03-30
JP2015083609A (ja) 2015-04-30
MX337061B (es) 2016-02-11
ECSP088500A (es) 2008-07-30
MA29976B1 (fr) 2008-11-03
RU2010152367A (ru) 2012-06-27
KR20190026048A (ko) 2019-03-12
AU2006311803C1 (en) 2015-05-14
AU2006311803A1 (en) 2007-05-18
CA2624393C (en) 2016-01-05
SG10201804008UA (en) 2018-06-28
EP2998318A1 (de) 2016-03-23
JP2017095522A (ja) 2017-06-01
EP1942922A2 (de) 2008-07-16
EP2500030A3 (de) 2012-11-21
RU2583927C2 (ru) 2016-05-10
NZ594285A (en) 2013-02-22
DK2500030T3 (en) 2015-10-19
DK2500030T4 (en) 2018-10-29
PL2500030T5 (pl) 2019-02-28
RU2008122341A (ru) 2009-12-10
JP2015157862A (ja) 2015-09-03
CN107929731A (zh) 2018-04-20
CR10041A (es) 2008-12-03
JP2009514888A (ja) 2009-04-09
ES2551202T3 (es) 2015-11-16
MY151064A (en) 2014-03-31
BRPI0619657A2 (pt) 2011-11-08
MX2018014357A (es) 2020-09-14
ES2551202T5 (es) 2018-11-30
US8753625B2 (en) 2014-06-17
EP2500030A2 (de) 2012-09-19
HK1175718A1 (zh) 2013-07-12
MX360959B (es) 2018-11-23
US20180334495A1 (en) 2018-11-22
NO20082483L (no) 2008-08-01
EP2500030B1 (de) 2015-07-22
KR20180002911A (ko) 2018-01-08
US20140335078A1 (en) 2014-11-13
EP3299027A1 (de) 2018-03-28
EP1942922A4 (de) 2011-03-30
SI2500030T2 (sl) 2018-11-30
CA2903896A1 (en) 2007-05-18
ZA201300649B (en) 2014-10-29
PH12013501270B1 (en) 2016-02-01
PH12013501270A1 (en) 2016-02-01
AU2006311803B2 (en) 2012-11-01
JP2013049724A (ja) 2013-03-14
SI2500030T1 (sl) 2015-10-30
IL263237A (en) 2018-12-31
US20090214538A1 (en) 2009-08-27
IL250772A0 (en) 2017-04-30
CA2624393A1 (en) 2007-05-18
KR101511787B1 (ko) 2015-04-13
HUE026423T2 (en) 2016-05-30
EP2500030B2 (de) 2018-08-08
JP2019043963A (ja) 2019-03-22
NZ567483A (en) 2012-04-27
KR20130137716A (ko) 2013-12-17
HK1223106A1 (zh) 2017-07-21
UA99591C2 (ru) 2012-09-10

Similar Documents

Publication Publication Date Title
IL263237A (en) Use of complement pathway inhibitors to treat eye diseases
HK1222537A1 (zh) 用於治療疾病或病症的液體製劑
IL189025A0 (en) Use of heat shock to treat ocular disease
SI2056863T1 (sl) Zdravljenje očesnih bolezni
GB0610867D0 (en) Treatment of pain
HK1201046A1 (en) Methods of treating ophthalmic diseases
EP2187743A4 (de) Formulierungen zur behandlung von augenerkrankungen oder -leiden
IL190779A0 (en) Compositions for treatment of eye diseases
HK1129689A1 (en) Targeting complement factor for treatment of diseases
HK1131047A1 (en) Treatment of inflammatory diseases
EP1919480A4 (de) Hedgehog-weg-antagonisten zur behandlung von krankheiten
EP2083862A4 (de) Zusammensetzungen und verfahren zur behandlung von augenerkrankungen und -leiden
IL193748A0 (en) Treatment of pain
PL2049127T3 (pl) N-metanokarbapochodne do leczenia chorób serca
EP2026822A4 (de) Topische behandlung für erkrankungen der augenoberfläche
ZA200806808B (en) Treatment of stressed patients
EP1988889A4 (de) Zusammensetzungen und verfahren zur behandlung von ophtamlischen erkrankungen und störungen
EP2025342A4 (de) Therapeutisches mittel oder entwicklungshemmer von polyglutamin-krankheit
GB0623740D0 (en) Treatment of disease
GB0616450D0 (en) Treatment of pain
BRPI0716580A2 (pt) Tratamento de distúrbios fibrosantes
ZA200906883B (en) Methods of treating ophthalmic diseases